How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%

Core Viewpoint - Enliven Therapeutics, Inc. (ELVN) shows significant upside potential with a mean price target of $41.13, indicating a 102.4% increase from its current trading price of $20.32 [1][2]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $6.66, suggesting variability in analyst predictions. The lowest estimate is $33.00 (62.4% increase), while the highest is $52.00 (155.9% increase) [2]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ELVN's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 5.3% over the last 30 days, with two estimates moving higher and no negative revisions [11][12]. - ELVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside in the near term [13]. Caution on Price Targets - While price targets are often sought after by investors, they can be misleading. Empirical research suggests that price targets rarely indicate actual stock price movements, and analysts may set overly optimistic targets due to business incentives [7][8][10].